Ca2+ signalling and muscle disease

European Journal of Biochemistry

Volumn 267, Issue 17, 2000, Pages 5291-5297

  MacLennan, David H ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Brody disease; Cardiomyopathy; Central core disease; Malignant hyperthermia

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); CALCIUM ION; PHOSPHOLAMBAN; CALCIUM BINDING PROTEIN; CALCIUM CHANNEL L TYPE; CALRETICULIN; CALSEQUESTRIN; RIBONUCLEOPROTEIN;

CALCIUM MOBILIZATION; CARDIOMYOPATHY; EXERCISE; HEART MUSCLE CONTRACTILITY; HUMAN; MALIGNANT HYPERTHERMIA; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SARCOPLASMIC RETICULUM; SHORT SURVEY; SIGNAL TRANSDUCTION; ANIMAL; CALCIUM SIGNALING; CENTRAL CORE DISEASE; GENETICS; METABOLISM; MOUSE; MOUSE MUTANT; MUTATION; REVIEW; TRANSGENIC MOUSE;

ANIMALS; CALCIUM CHANNELS, L-TYPE; CALCIUM SIGNALING; CALCIUM-BINDING PROTEINS; CALRETICULIN; CALSEQUESTRIN; HUMANS; MALIGNANT HYPERTHERMIA; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MUTATION; MYOPATHY, CENTRAL CORE; RIBONUCLEOPROTEINS;

EID: 0033624484     PISSN: 00142956     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1432-1327.2000.01566.x     Document Type: Short Survey

References (78)

1. Calcium - A life and death signal
2. Ion tamers
3. Mechanism of direct coupling between binding and induced structural change in regulatory calcium binding proteins
4. Calcium binding and conformational response in EF-hand proteins
5. Mitochondria and apoptosis
6. Ryanodine receptors of striated muscles: A complex channel capable of multiple interactions
7. Intracellular calcium homeostasis
8. Phospholamban: Protein structure, mechanism of action, and role in cardiac function
9. 2+-ATPase
10. Calcium pump of the plasma membrane
11. Crystal structure of calsequestrin from rabbit skeletal muscle sarcoplasmic reticulum
12. Malignant hyperthermia
13. A mutation in the human ryanodine receptor gene associated with central core disease
14. Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia
15. Malignant-hyperthermia susceptibility is associated with a mutation of the α1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle
16. 2+ ATPase, are associated with Brody disease
17. The transgenic expression of highly inhibitory monomeric forms of phospholamban in mouse heart impairs cardiac contractility
18. Cardiac-specific overexpression of a super-inhibitory pentameric phospholamban mutant enhances inhibition of cardiac function in vivo
19. 2+ signaling in transgenic mouse cardiac myocytes overexpressing calsequestrin
20. Calreticulin is essential for cardiac development
21. 2+ transporting ATPases
22. Etiopathogenetic defect of malignant hyperthermia: Hypersensitive calcium-release channel of skeletal muscle sarcoplasmic reticulum
23. Central core disease. A correlated genetic, histochemical, ultramicroscopic, and biochemical study
24. Central core disease: Ultrastructure of the sarcoplasmic reticulum and T-tubules
25. A new congenital non-progressive myopathy
26. Central core disease. Clinical features in 13 patients
27. Oxidative enzymes and phosphorylase in central-core disease of muscle
28. Central core disease of muscle: Clinical, histochemical and electron microscopic studies of an affected mother and child
29. Central-core disease and malignant hyperpyrexia
30. Malignant hyperthermia: Relationship to other diseases
31. 2+ release channel function and severe central core disease
32. 2+ release channel (ryanodine receptor) of rabbit cardiac muscle sarcoplasmic reticulum
33. The structural organization of the human skeletal muscle ryanodine receptor (RYR1) gene
34. Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia
35. Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2
36. Assignment of the gene for central core disease to chromosome 19
37. Evidence for linkage of the central core disease locus to the proximal long arm of human chromosome 19
38. Refined genetic localization for central core disease
39. Multipoint mapping of the central core disease locus
40. 2+ release channels
41. A clinical grading scale to predict malignant hyperthermia susceptibility
42. Clinical reassessment of malignant hyperthermia in Abitibi-Temiscamingue
43. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility
44. Standardization of the caffeine halothane muscle contracture test. North american malignant hyperthermia group
45. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the european MH Group: Results of testing patients surviving fulminant MH and unrelated low-risk subjects. The european malignant hyperthermia group
46. The sensitivity and specificity of the caffeine-halothane contracture test: A report from the north american malignant hyperthermia registry. The north american malignant hyperthermia registry of MHAUS
47. Evidence for the localization of a malignant hyperthermia susceptibility locus (MHS2) to human chromosome 17q
48. Anesthetic complications in muscle disorders
49. Masseter muscle rigidity associated with glycine1306-to-alanine mutation in the adult muscle sodium channel alpha-subunit gene
50. A genome wide search for susceptibility loci in three european malignant hyperthermia pedigrees
51. Missense mutations in the beta-myosin heavy-chain gene cause central core disease in hypertrophic cardiomyopathy
52. 2+ release is altered by 15 calcium release channel (ryanodine receptor) mutations associated with malignant hyperthermia and/or central core disease
53. 2+ release channels
54. Muscle contracture induced by exercise. A syndrome attributable to decreased relaxing factor
55. 2+- ATPase of human fast-twitch skeletal muscle sarcoplasmic reticulum, and its elimination as a candidate gene for Brody disease
56. 2+ ATPase genes: Homologies and mechanistic implications of deduced amino acid sequences
57. 2+-adenosine triphosphatase in sarcoplasmic reticulum (Brody's disease)
58. Sarcoplasmic reticulum adenosine triphosphatase deficiency with probable autosomal dominant inheritance
59. 2+-ATPase deficiency in a patient with an exertional muscle pain syndrome
60. 2+ homeostasis in Brody's disease. A study in skeletal muscle and cultured muscle cells and the effects of dantrolene an verapamil
61. Characterization of the gene encoding human sarcolipin (SLN), a proteolipid associated with SERCA1: Absence of structural mutations in five patients with Brody disease
62. 2+ uptake in mammalian ventricular myocytes
63. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation
64. Phospholamban: A prominent regulator of myocardial contractility
65. Cardiac-specific overexpression of phospholamban alters calcium kinetics and resultant cardiomyocyte mechanics in transgenic mice
66. β-Adrenergic regulation of cAMP and protein phosphorylation in phospholamban-knockout mouse hearts
67. Purification and characterization of phospholamban from canine cardiac sarcoplasmic reticulum
68. Structural organization of the pentameric transmembrane alpha-helices of phospholamban, a cardiac ion channel
69. A leucine zipper stabilizes the pentameric membrane domain of phospholamban and forms a coiled-coil pore structure
70. Phospholamban inhibitory function is activated by depolymerization
71. 2+ pump and phospholamban in Spodoptera frugiperda (Sf21) cells reveals new insights on ATPase regulation
72. 2+-ATPase isoform of cardiac sarcoplasmic reticulum
73. 2+ channel in transgenic mice. Loss of isoproterenol-induced contraction
74. Calreticulin: One protein, one gene, many functions
75. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy